No title
The development of generic pharmaceuticals includes extensive data on equivalence with the reference listed drug is required by the European medicinal agency (EMA) and the North American equivalent. Equivalence must be proven for rheology, microstructure, and performance. This is a costly and time-consuming process. To reduce the costs, it is of interest to investigate if the release profile (perf
